🔗 Share this article

While the United States continues making unprecedented changes to its immunization schedules, one figure appears unexpectedly: Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by casting doubt on coronavirus vaccinations in the pandemic and has focused upon alleged deaths following COVID-19 immunization in her short tenure at the Food and Drug Administration.

Scheduled Overhauls to Childhood Vaccine Program

Health officials planned to unveil sweeping revisions to the childhood immunization program in December, synchronizing the US with Denmark’s national calendar, sources say – a substantial departure that would place the US at odds with a large portion of the global community with little proof for public health gain. The planned update has been postponed until the next year.

Rather than Vinay Prasad, Høeg is listed to address the audience at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the division this year.

A Shift at the Agency

The acting appointment may indicate a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a increased emphasis upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for halting some pediatric vaccine recommendations in the US in order to be more in line with Denmark, a society with comprehensive healthcare and a number of inhabitants approximately the size of the state of Wisconsin.

So far statements, she has kept her attention on immunizations – typically the purview of Dr. Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Expertise

The appointee has little discernible track record in medication creation, regulation or leadership, which has been customary for former leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in leading a large organization. She is not an expert in drug approvals.”

Former heads of the center would “understand legal statutes and the underlying principles of drug development”, noted Janet Woodcock. “Frankly, she doesn’t have the kind of background that prior appointees who ran the center have had.”

The drug center has an immense portfolio at the agency, the former commissioner stated.

“Everybody just focuses on the new drug program, but the off-patent medication office authorizes numerous generic medications. There’s a biologic copycat branch, non-prescription drug unit and other areas, and each of these need to be managed,” Woodcock explained. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

Additionally, a major administrative component to the job, which supervises more than 5,000 staff members. “It’s a massive administrative position, if you perform it correctly,” the former official concluded.

Official Statement and Disputed Programs

When asked about inquiries about Dr. Høeg's fitness for the role and whether this selection represents greater collaboration among FDA leaders on vaccines, a representative responded that the “concerns stem from incorrect premises”.

“Her resume matches the duties of her role,” the representative stated, citing the months Dr. Høeg spent counseling the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg inherits the agency head's recently launched priority voucher program, a disputed one-day therapy clearance system that reportedly troubled her predecessors. “How are these therapies being picked for this fast-track system? Who makes the choices?” Howard said. “There is a lot of confidentiality occurring at the agency right now.”

Broadly speaking, he remarked, “the FDA appears to be shifting towards more relaxed rules of all drugs, with the exception of vaccines.”

Established History on Immunizations

Concerning immunizations, Høeg has a more established, if concerning, track record, some experts said. She published a research paper using unverified volunteer-provided data to determine the rate of heart inflammation following COVID-19 vaccination. She consulted for the Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to imply Covid vaccines are riskier than they are.

Part of her “wish list” for the incoming administration featured altering rules for recently developed shots and ending “unnecessary” vaccines, she stated following the vote on a audio program. At the agency, Høeg has reportedly suggested excluding adolescent males from receiving Covid vaccines.

“She is an complete dogmatist who commences with her preconceived notions and tailors the evidence to fit the science in a very misleading, untruthful manner,” Dr. Howard said.

Taking Control and a “Push for Payback”

Høeg joined fellow skeptics, {like|